Innovative polatuzumab vedotin plus R-CHP therapy reshapes treatment of older adult patients with diffuse large B-cell lymphoma.

Nipocalimab led to sustained MG-ADL and QMG improvements over 84 weeks with long-term IgG reduction in gMG patients. 45% of ...